How Residual Disease and Recurrence (RDR) Testing using Liquid Biopsy is Changing Clinical Trial Design
About the presenter
Nitzan Rosenfeld PhD is a world-leader in circulating tumor DNA research and since 2009 leads a research group at the Cancer Research UK Cambridge Institute, part of the University of Cambridge, he is also co-founder and CSO of Inivata. His work combines new molecular and genomics approaches to develop new diagnostic tools and applications. Previously he was head of Computational Biology at Rosetta Genomics, where he led development of molecular diagnostic tests for cancer. Nitzan has authored multiple patents and research articles on methods for molecular diagnostics and cell-free DNA analysis and has been awarded the CRUK Future Leaders in Cancer Research prize, the British Association for Cancer Research Translational Research Award, the Academy of Medical Sciences Foulkes Medal and most recently he received the 2020 Cancer Researcher Award from the European Association for Cancer Research and Pezcoller Foundation.